A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Investigator: Maen Abdelrahim, MD

Study Coordinator: Safiya Joseph

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT03816163

Phone: 203.308.8567

Protocol Number: Pro00022270


The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evaluate other anti-tumor effects, tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM. UNDER TEMPORARY HOLD FROM SPONSOR DUE TO COVID19
More to Explore